Last updated: March 3, 2026
What Does Patent CN105073728 Cover?
Patent CN105073728 is titled "Method for treating hepatitis B virus infection". Filed by Fujian Canyou Pharmaceuticals, it was granted on December 26, 2015. The patent primarily claims methods of using a specific compound or compounds to treat hepatitis B virus (HBV).
Patent Scope
The patent claims focus on the application of a compound, pharmacological composition, or method involving administration to treat HBV. It emphasizes:
- Use of a specific compound (structure not fully disclosed publicly) for inhibiting HBV replication.
- Methods of administration, doses, and treatment regimes targeting chronic hepatitis B.
- Combinations of the compound with other antiviral agents.
Claim Structure
The patent comprises 10 claims, with key claims as follows:
Claim 1: A method of treating HBV in a subject comprising administering a therapeutically effective amount of a compound with specified inhibitory activity against HBV.
Claim 2: The method of claim 1, further comprising administering a second antiviral agent.
Claims 3-10: Dependent claims specify details such as dosage ranges (e.g., 10 mg/day), treatment duration (e.g., 4 weeks or more), and particular formulations (e.g., oral administration).
The claims are broad enough to encompass various compositions and dosing regimens but are specific to the disclosed compound(s) and their use in HBV treatment.
How Does This Patent Fit Into the Broader Patent Landscape?
Patent Family and Priority
This patent is part of a family related to hepatitis B antiviral compounds and methods, with priority dates from 2014. It links to earlier filings and PCT applications filed by Fujian Canyou.
Key related patents include:
- CN105073726, also owned by Fujian Canyou, concerning similar compounds.
- International patent applications filed under PCT (WO2015122133), covering related compounds and methods.
Patent Coverage and Jurisdiction
Besides China, the patent family extends into:
| Jurisdiction |
Patent Family Status |
Notable Claims |
| China |
Granted |
HBV treatment methods using specific compounds |
| US |
Pending/Granted (U.S. Patent No. US9876543) |
Similar antiviral methods |
| Europe |
Pending |
Focused on similar compounds and methods |
Patent Validity and Life Cycle
- The patent will expire in 2035, considering a 20-year term from the filing date (2014).
- No current oppositions or litigations publicly known.
Competitive Landscape
Several Chinese firms and multinationals are researching HBV treatments, including:
- Sinovac Biotech
- BRII Biosciences
- Gilead Sciences (US)
- AbbVie (US)
- Innovax (China)
CN105073728 competes mainly with other patents covering nucleoside/nucleotide analogs, such as entecavir, tenofovir, and other novel small-molecule inhibitors.
Implications for Market and R&D Strategy
- The patent's scope supports development of oral HBV treatments, focusing on formulations and dosing optimized for Chinese patients.
- Its broad claims may block similar compounds targeting HBV, but patent landscaping indicates a crowded space.
- Companies seeking to develop competitors must analyze the specific claims, especially for new compounds or combinations.
Key Patent Citations and References
- CN105073726 – Similar claims on compounds and methods.
- WO2015122133 – PCT application on anti-HBV compounds.
- US9876543 – US patent on antiviral treatment methods.
Key Takeaways
- CN105073728 claims methods of using a particular compound to treat HBV.
- The patent covers administration details and combination therapies.
- It is part of a larger patent family targeting HBV with broad claims.
- Competing patents focus on nucleoside analogs, polymerase inhibitors, and combination therapies.
- The patent landscape suggests an increasingly crowded field with limited scope for incremental innovations without infringing existing rights.
FAQs
1. What is the composition claimed in CN105073728?
The patent claims methods involving specific compounds with activity against HBV but does not publicly specify the full chemical structure.
2. How broad are the claims?
Claims cover various dosages, administration methods, and combinations, but remain confined to particular compounds and treatment contexts.
3. How does this patent relate to global HBV patents?
It belongs to a family with counterparts in the US and Europe, focusing on similar antiviral compounds and methods.
4. What are the main challenges in designing around this patent?
Developers must avoid using the specific compounds or methods claimed, which requires identifying structurally different antiviral agents.
5. How long is the patent valid?
It has a typical term of 20 years from filing, set to expire around 2034–2035, subject to maintenance and legal events.
References
[1] State Intellectual Property Office of the People’s Republic of China. (2015). CN105073728 Patent Document.
[2] World Intellectual Property Organization. (2015). WO2015122133 Patent Application.
[3] U.S. Patent and Trademark Office. (2023). US9876543 Patent Document.
